Precision-Guided Dosing

PredictrPK tests are laboratory-developed tests that were developed, and analytically and clinically validated by Prometheus Laboratories Inc. under federal Clinical Laboratory Improvement Amendments (CLIA) guidelines, and are performed exclusively in our high complexity CLIA-certified (05D0917432) and College of American Pathologists-accredited (6805501) clinical laboratory. As laboratory developed tests, they have not been cleared or approved by the US FDA. These tests may be covered by one or more US pending or issued patents – see prometheuslabs.com/patents. PredictrPK IFX Maintenance and IFX Induction tests are validated for IBD patients receiving intravenous IFX. PredictrPK ADA is validated for IBD patients ≥12 years old. PredictrPK VDZ (intravenous only) and UST Maintenance are validated for IBD patients ≥18 years. This material is provided for general information purposes only as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.